Log in
Enquire now
‌

US Patent 11376327 Stable transdermal amphetamine compositions and methods of manufacture

Patent 11376327 was granted and assigned to Noven Pharmaceuticals on July, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Noven Pharmaceuticals
Noven Pharmaceuticals
0
Current Assignee
Noven Pharmaceuticals
Noven Pharmaceuticals
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
113763270
Patent Inventor Names
Jun Liao0
Prashant Patel0
Viet Nguyen0
Date of Patent
July 5, 2022
0
Patent Application Number
158271900
Date Filed
November 30, 2017
0
Patent Primary Examiner
‌
Genevieve S Alley
0
CPC Code
‌
A61K 9/7007
0
‌
A61K 31/137
0
‌
A61L 31/129
0
‌
A61K 9/0014
0
‌
A61K 47/32
0

Described are transdermal drug delivery compositions comprising amphetamine, methods of making transdermal drug delivery compositions comprising amphetamine, and therapeutic methods of using them. In specific embodiments, the compositions are free of components with moieties that are reactive with amphetamine. In specific embodiments, the compositions are manufactured using solvents free of components with moieties that are reactive with amphetamine. Therapeutic methods using the compositions also are described.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11376327 Stable transdermal amphetamine compositions and methods of manufacture

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.